SCHEMBL3569445

SCHEMBL3569445

CN1CCN=C1c1ccc(NC(=O)C(CC(=O)NCc2ccccc2)NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
F10 P00742 5/20 0.41
UTS2R Q9UKP6 1/20 0.41
CHRM1 P11229 1/20 0.40
HTR2A P28223 1/20 0.40
MCHR1 Q99705 1/20 0.40
CCKBR P32239 1/20 0.40
CNR1 P21554 1/20 0.39
KDM1A O60341 1/20 0.39
HPGD P15428 1/20 0.39
PSD A5PKW4 1/20 0.39
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
F7 P08709 1/20 0.38
LSS P48449 1/20 0.38
EP300 Q09472 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567334 0.91 UTS2R (0.43) MAPTF10UTS2RCCKBRCNR1
SCHEMBL3566371 0.88 FPR2 (0.45) F10UTS2REP300
SCHEMBL3569854 0.87 F10 (0.44) F10UTS2RCCKBRCNR1
SCHEMBL3567021 0.87 F10 (0.46) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3562613 0.87 F10 (0.46) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3562133 0.87 F10 (0.46) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3560576 0.86 CCKBR (0.48) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3559100 0.86 CCKBR (0.48) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3564964 0.86 CCKBR (0.48) MEN1KMT2AMAPTF10UTS2R
SCHEMBL3563910 0.84 F10 (0.45) MEN1KMT2AMAPTF10UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 MEN1 2311/4885KMT2A 4014/4885MAPT 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.